Science & Innovation

By Rachael Rettner, Senior Writer |

A new cancer “vaccine” that’s injected directly into a single tumor can trigger the immune system to attack cancer cells throughout the body, a small new study suggests.

Full article

February 1, 2019 | Oncology Central

The National Institute for Health and Care Excellence (NICE) has approved Novartis’ CAR-T therapy Kymriah® (tisagenlecleucel) for the treatment of diffuse large B-cell lymphoma in adults, following a commercial agreement with NHS England.
Read more

January 26, 2019 | Oncology Central

Cancer advancements 2018–2019

During 2018 immuno-oncology once again was an immensely popular hot topic. At both the American Association for Cancer Research Annual Meeting 2018 (AACR, April 14–18, IL, USA) and the American Society of Clinical Oncology Annual Meeting (ASCO, 1–5 June 2018, IL, USA) several key studies were presented, which highlighted high success rates with novel immuno-oncology combinations.

Read more

Immunotherapy experts discuss the latest cancer immunotherapy advances featured the 2018 annual meeting of the American Society of Clinical Oncology (ASCO).


– combination immunotherapy
– biomarker development
– CAR T cell therapies
– new approaches to immune-based cancer treatment.

Panelists include Charles G. Drake, M.D., Ph.D., of New York-Presbyterian/Columbia University Medical Center, and Catherine Diefenbach, M.D., and Jeffrey S. Weber, M.D., of the Perlmutter Cancer Center at NYU Langone Health. Jill O’Donnell-Tormey, Ph.D., of the Cancer Research Institute, moderates.

Watch Video

Video and information source: Cancer Resource Institute

New York Time Article July 30, 2016
New drugs and methods of altering a patient’s own immune cells are helping some cancer patients – bu not all – even when standard treatments fail.
Read more